Ethics committee

Virax Biolabs Receives Ethical Approval for its Virax Immune COVID-19 Analytical Performance Study from the SBEBO Foundation for the Assessment of Ethics of Biomedical Research

Retrieved on: 
星期一, 五月 9, 2022
Antibody, COVID-19, Forward-looking statement, Immune system, Herpes simplex, Degenerative disease, GLOBE, Assessment, Company, Biotechnology, Biomedical Research, Ethics committee, Diagnosis, Environment, Therapy, Hepatitis B, Intention, Disease, Terminology, Technology, Growth, IVD, Nature, Vaccine, Malaria, Ethics

The Ethics Committee is an independent Medical Research Ethics Committee for biomedical scientific research involving human subjects taking place within the Netherlands.

Key Points: 
  • The Ethics Committee is an independent Medical Research Ethics Committee for biomedical scientific research involving human subjects taking place within the Netherlands.
  • The Analytical Performance Study will evaluate the technical performance of the Virax Immune COVID-19 Flow Cytometry Kit.
  • Virax Immune is a new In-Vitro Diagnostic (IVD) test seeking detection of T-Cell immune responses to viral threats such as COVID-19 and its variants.
  • "We are pleased to take this critical step towards kicking off our upcoming Analytical Performance Study for the Virax Immune IVD Testing Device, commented James Foster, Chief Executive Officer of Virax.

Boutique Midtown Atlanta Law Firm Bloom Lines Alexander LLC Continues Tradition of Serving Georgia Families Started Over 30 Years Ago

Retrieved on: 
星期三, 四月 6, 2022
Consulting, Legal, Professional Services, Finance, Georgia Trend, Heart, Ethics committee, Retirement, Multimedia, Melody, Atlanta (magazine), Publication, Woman, Divorce, Knowledge, American Psychological Association, Child, Lawyer, Management, Atlanta

Bloom Lines Alexander LLC continues that mission today in the very same offices where the vision first started over three decades prior.

Key Points: 
  • Bloom Lines Alexander LLC continues that mission today in the very same offices where the vision first started over three decades prior.
  • And while the mission remains the same, the experience, expertise, and breadth of knowledge at Bloom Lines Alexander LLC has only continued to grow.
  • While the name Bloom Lines Alexander LLC may be new, the proven results of the dedicated attorneys at the firm are not.
  • I am very excited to show Georgia families that Bloom Lines Alexander LLC is a name they can count on when faced with newfound uncertainty.

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases

Retrieved on: 
星期四, 三月 24, 2022
Research, Other Health, General Health, Pharmaceutical, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, Company, Private Securities Litigation Reform Act, MUC5AC, Arrowhead Pharmaceuticals, Therapy, NASDAQ, Ethics committee, D, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Committee, Clinical trial, Pharmacokinetics, Mission statement, RNA, U.S. Securities and Exchange Commission, Arrowhead, RNA interference, Mucus, Review, Safety, Twitter, COVID-19, MBA, Gene, Gene silencing, News, Asthma, Annual report, Patient, Security (finance), Pharmaceutical industry

Arrowhead also announced plans to host a pulmonary R&D day on May 26, 2022, to be held in New York and webcast online.

Key Points: 
  • Arrowhead also announced plans to host a pulmonary R&D day on May 26, 2022, to be held in New York and webcast online.
  • Additional details about the event and how to register will be released in the coming weeks.
  • We look forward to sharing additional information about ARO-MUC5AC, ARO-RAGE, and Arrowheads pulmonary platform broadly at our upcoming pulmonary R&D day.
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

MAIA Biotechnology, Inc. Announces HREC Approval in Australia for its THIO-101 Phase 2 Trial for NSCLC

Retrieved on: 
星期二, 三月 15, 2022
Oncology, Health, Other Health, Clinical Trials, General Health, Biotechnology, Survival, Endpoint security, Patient, MAIA, Forward-looking statement, Safety, Ethics, Ethics committee, ORR, Research, Cancer, Regeneron Pharmaceuticals, Growth, View, PD-1, Immune system, Biotechnology, Pharmaceutical industry, NSCLC, Sanofi, THIO-101, a Phase 2 Clinical Trial, THIO, MAIA Biotechnology, Inc., THIO-101, A PHASE 2 CLINICAL TRIAL, THIO, MAIA BIOTECHNOLOGY, INC.

In the near term, we look forward to dosing our first patient with THIO in this Phase 2 study.

Key Points: 
  • In the near term, we look forward to dosing our first patient with THIO in this Phase 2 study.
  • THIO (6-thio-dG or 6-thio-2-deoxyguanosine) is a telomere-targeting agent currently in clinical development to evaluate its activity in NSCLC.
  • MAIA cautions that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements.
  • In this release, unless the context requires otherwise, MAIA, Company, we, our, and us refers to MAIA Biotechnology, Inc. and its subsidiaries.

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma

Retrieved on: 
星期二, 三月 15, 2022
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, RNA interference, Twitter, Trial of the century, MBA, Pharmacokinetics, Private Securities Litigation Reform Act, Annual report, Review, Patient, News, RAGE, Therapy, COVID-19, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Arrowhead, Safety, Arrowhead Pharmaceuticals, Committee, Security (finance), Asthma, NASDAQ, Gene silencing, Ethics committee, Clinical trial, Company, Serum, U.S. Securities and Exchange Commission, Gene, Mission statement, RNA, Pharmaceutical industry

James Hamilton, M.D., MBA, senior vice president of discovery and translational medicine at Arrowhead, said: ARO-RAGE is a new clinical candidate using the pulmonary targeted, inhaled TRiM platform.

Key Points: 
  • James Hamilton, M.D., MBA, senior vice president of discovery and translational medicine at Arrowhead, said: ARO-RAGE is a new clinical candidate using the pulmonary targeted, inhaled TRiM platform.
  • We believe RAGE is a promising target as it represents an upstream mediator of the inflammatory cascade in asthma.
  • Importantly, a soluble form of RAGE known as sRAGE can be assessed as a useful serum biomarker to measure gene target knockdown.
  • Pending clearance, Arrowhead intends to proceed with ARORAGE-1001, a Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-RAGE in up to 64 healthy volunteers and in up to 16 patients with asthma.

Tannenbaum Helpern's Vincent J. Syracuse is the recipient of the 2022 Sanford D. Levy Professional Ethics Award

Retrieved on: 
星期四, 二月 17, 2022
Creativity, Judgement, Ethics, Ethics committee, New York State Bar Association, NYSBA, Joan Helpern, Commercial, Syracuse, Twitter, Committee, Professional, Lawyer, Private law, Program, Continuing legal education, Practice of law

NEW YORK, Feb. 17, 2022 /PRNewswire-PRWeb/ --Tannenbaum Helpern is thrilled to announce that Vincent J. Syracuse is the 2022 recipient of the New York State Bar Association's Sanford D. Levy Professional Ethics Award.

Key Points: 
  • NEW YORK, Feb. 17, 2022 /PRNewswire-PRWeb/ --Tannenbaum Helpern is thrilled to announce that Vincent J. Syracuse is the 2022 recipient of the New York State Bar Association's Sanford D. Levy Professional Ethics Award.
  • This award, created in 1982, annually recognizes an individual or institution that has made a significant contribution to the understanding of professional ethics.
  • Syracuse, a founding partner of Tannenbaum Helpern's Litigation and Dispute Resolution practice, has spent over fifty years raising the standard of ethics and civility in the practice of law.
  • On February 16, 2022 the Ethics Committee of the NYSBA honored Syracuse with the award virtually.

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

Retrieved on: 
星期一, 二月 14, 2022
Psilocybin, Patient, Orphan drug, Ischemia, Reperfusion injury, CEO, Company, Coronavirus, Infection, Death, Ethics committee, RVV, Goal, Safety, Therapy, Autoimmune hepatitis, Disorder, FDA, Inflammation, Acquisition, Liver disease, COVID-19 deaths, CSE, Research, COVID-19, Organ transplantation, GLOBE, Drug development, Pharmaceutical industry, CBD

The Company is working with MLP Care, the largest hospital group in Turkey, and Istinye University with access to 30 clinical research sites and over 6000 in-patient hospital beds.

Key Points: 
  • The Company is working with MLP Care, the largest hospital group in Turkey, and Istinye University with access to 30 clinical research sites and over 6000 in-patient hospital beds.
  • The Company has initially selected the following 13 clinical research sites in Turkey:
    Covid-19 infections in Turkey continues to grow.
  • Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19.
  • With its acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders.

Atossa Therapeutics Announces Advancement to Part B of Clinical Study of AT-H201

Retrieved on: 
星期二, 一月 18, 2022
Forward-looking statement, ATOS, Patient, Atossa, Form 10-K, COVID-19, Severe acute respiratory syndrome coronavirus 2, B cell, Safety, Breast cancer, GLOBE, Breast, U.S. Securities and Exchange Commission, Nasdaq, Ethics committee, Infection, Therapy, FDA, Security (finance), Coronavirus, Omicron, Pharmaceutical industry, Part

Part A of the study, which consisted of a single ascending dose group of 4 cohorts of healthy participants, has now been completed.

Key Points: 
  • Part A of the study, which consisted of a single ascending dose group of 4 cohorts of healthy participants, has now been completed.
  • The Australian Human Research Ethics Committee has reviewed the safety data from Part A and has approved the study to proceed to Part B.
  • A record number of hospitalizations driven by the Omicron variant is producing a crisis at many healthcare facilities.
  • The Phase 1/2a placebo-controlled study will enroll a total of 60 healthy participants and moderately-ill hospitalized COVID-19 patients.

Ed Murray elected for fifth year in a row as president of California Solar and Storage Association

Retrieved on: 
星期五, 十二月 17, 2021
Solar energy, Ethics committee, Education, Murray, Country, Solar Energy Industries Association, CEO, Solar, SEIA, Commonwealth, Policy, Technology, Renewable energy

RANCHO CORDOVA, Calif., Dec. 17, 2021 /PRNewswire-PRWeb/ --Ed Murray, CEO of Aztec Solar, Powered By Sigora, has been re-elected as president of the California Solar and Storage Association (CALSSA) for the fifth year in a row.

Key Points: 
  • RANCHO CORDOVA, Calif., Dec. 17, 2021 /PRNewswire-PRWeb/ --Ed Murray, CEO of Aztec Solar, Powered By Sigora, has been re-elected as president of the California Solar and Storage Association (CALSSA) for the fifth year in a row.
  • CALSSA is an advocate for solar energy storage, standards and codes, solar heating and cooling, net metering, lowering costs, and expanding solar access.
  • Murray has represented all aspects of solar, including utility-scale solar systems, swimming pool solar heating and solar water systems, and rooftop distributed energy.
  • The company offers in-house solar water heating, solar storage, solar pool heating and solar electric experience for all applications, from small-scale residential projects to large-scale commercial projects.

Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical Trials

Retrieved on: 
星期三, 十一月 10, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, American Association, CTA, Enrollment, Therapy, Director, Regulation Fair Disclosure, D, Non-alcoholic fatty liver disease, COVID-19, Â, American Journal, Disclosure, Risk, Laurent, University of Oxford, Safety, Fatty liver disease, Recurrence, Compte rendu, MHRA, PASC, Degenerative disease, Trial of the century, University, Association, NASH, Research, Annual general meeting, EMM, Medicines and Healthcare products Regulatory Agency, The American Journal of Gastroenterology, Patient, FDA, Emms, Health care, Private Securities Litigation Reform Act, Inflammation, AASLD, United, Program, Fatigue, Metabolism, SEC, Science, Biological activity, Institute of Liver and Biliary Sciences, OHE, Board, Homeostasis, Ethics committee, Fibrosis, Regulation, IND, Pharmaceutical industry, Dietary supplement

The third quarter of 2021 was a time in which Axcella focused heavily on both execution and expansion, said Bill Hinshaw, President and Chief Executive Officer of Axcella.

Key Points: 
  • The third quarter of 2021 was a time in which Axcella focused heavily on both execution and expansion, said Bill Hinshaw, President and Chief Executive Officer of Axcella.
  • Progressed Screening and Enrollment in EMMPOWER and EMMPACT Clinical Trials: Patient screening and enrollment continues in Axcellas recently initiated EMMPOWER Phase 2 clinical trial in overt hepatic encephalopathy (OHE) and EMMPACT Phase 2b clinical trial in nonalcoholic steatohepatitis (NASH).
  • Published AXA1125 Data in The American Journal of Gastroenterology: The American Journal of Gastroenterology recently published results from Axcellas AXA1125-003 clinical study.
  • The companys unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials.